The Phase III studies of ivacaftor in patients did not include the NPD, and the Phase II study of VX-809 monotherapy in CF patients with two F508del CFTR mutations did not demonstrate improvement in the NPD or in clinical efficacy measures [29], [30]. This evidence concerns the gene CFTR and cystic fibrosis.